Inventiva S.A. develops oral small-molecule therapies as a clinical-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Company updates commonly center on lanifibranor, clinical-development activity, R&D spending, financing actions, and business updates tied to its French operations and American depositary shares.
News about IVA also includes governance and leadership changes, annual meeting materials, financial results, and portfolio actions such as licensing or divestiture activity involving non-core programs. The company's disclosures frame Inventiva as a foreign issuer with research expertise in nuclear receptors, transcription factors, and epigenetic modulation.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
FAQ
What is the current stock price of Inventiva (IVA)?
Inventiva (IVA) last closed at $3.685.
What is the market cap of Inventiva (IVA)?
The market cap of Inventiva (IVA) is approximately $870.5M.